Analyst Price Targets — AMRN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2023 5:23 am | — | Jefferies | $3.00 | $1.26 | Benzinga | Jefferies Upgrades Amarin Corp to Buy, Raises Price Target to $3 |
| May 24, 2022 7:21 am | — | Goldman Sachs | $1.50 | $1.41 | Benzinga | Goldman Sachs Maintains Sell on Amarin Corp, Lowers Price Target to $1.5 |
| May 5, 2022 12:00 am | Carl Byrnes | Northland Securities | $2.00 | $1.56 | TipRanks Contributor | Amarin Nosedives on Disappointing Quarterly Results |
Latest News for AMRN
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMRN.
U.S. House Trading
No House trades found for AMRN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.